| Indo-US Joint Network Centre for Excellence in Celiac Disease | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2019 |
| ENT COBRA: Standarized Data Collection (SDC) for head neck cancer patients treated with brachytherapy | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2020 |
| A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohns Disease | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2020 |
| A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2020 |
| Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to sever active ulcerative colitis | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2020 |
| Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to severely active crohn?s disease | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2021 |
| A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2022 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2022 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2022 |
| Association of Lipid mediators of inflammation with TB treatment outcomes | Life Sciences & Biotechnology, Medical Sciences | 2018 | 2019 |